ArticleThe Pan African medical journal2025
Home blood pressure monitoring and equity challenges of the 2025 ACC/AHA hypertension guideline in Africa.
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 2025 ACC/AHA hypertension guideline reaffirms < 130/80 mmHg as the treatment target and elevates home blood pressure monitoring (HBPM) as the diagnostic gold standard. While this represents progress in hypertension management, it risks widening inequities in Africa, where validated HBPM devices are scarce, unaffordable, and largely excluded from public health systems. Fewer than 10% of households in sub-Saharan Africa own a validated monitor, compared with more than 60% in high-income countries, and retail prices often exceed a week's income. Without deliberate policy action, accurate diagnosis and follow-up may become privileges reserved for wealthier populations, while most patients continue to rely on single clinic readings. Evidence from Ghana, Nigeria, Kenya, and Ethiopia highlights systemic barriers, including device shortages, weak procurement systems, financing gaps, and limited awareness, that undermine hypertension care. To align with international standards, African health systems must recognize HBPM as an essential health technology, add validated devices to national essential lists, and mobilize sustainable financing for procurement. Regional pooled purchasing, local manufacturing, and donor support could reduce costs and improve supply security. Embedding HBPM into hypertension pathways is not only a technical priority but also an equity imperative to close the global treatment gap.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.